Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Taladegib

Catalog No: tcsc0459

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1258861-20-9

Formula:
$C_{26}H_{24}F_4N_6O$

Pathway:
Stem Cell/Wnt

Target:
Smo

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 5.2 mg/mL (10.15 mM)

Alternative Names:
LY2940680

Observed Molecular Weight:
512.5

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Taladegib (LY2940680) is an antagonist of the **smoothened** receptor.

IC50 & Target: Smo[1]

In Vitro: Taladegib, a small-molecule antagonist of the smoothened receptor, shows a slight inhibitory effect on cell proliferation without differences between mucin- (IC_{50}: Taladegib=49.8±4.5 μM) and mixed- Cholangiocarcinoma (CCA) (IC_{50}: Taladegib=61.2±21.1 μM)[1]. The IC_{50} for Taladegib inhibition of [^{3}H]MRT-92 binding is right shifted (3- to 100-fold) for the S387A^{ECL2}, L325F$^{3.36f}$, and D473H$^{6.54f}$ mutants but did not differ from that of WT receptor for the other mutants. The ability of SANT-1 to inhibit [^{3}H]MRT-92 binding to V329F$^{3.40f}$ and T466F$^{6.47f}$ mutants is abolished, and it is severely impaired for L325F$^{3.40f}$, I408F$^{5.51f}$, and M525G$^{7.45f}$ mutants (4- to 140-fold drop of the IC_{50}), but is not modified for the S387A^{ECL2} mutant. Taken together, these data confirm our docking hypothesis that MRT-92-binding mode differs from that of either Taladegib or SANT-1 by simultaneously occupying binding sites 1 and 2[2].